Closure of persistent macular holes with human recombinant transforming growth factor-beta 2.

Abstract

OBJECTIVE:

To evaluate the efficacy of human recombinant transforming growth factor-beta 2 (TGF-beta 2) in the closure of persistent macular holes.

SETTING:

Retina service at a university-affiliated hospital in Vancouver.

PATIENTS:

Seventeen patients with macular holes who had previously undergone vitrectomy, posterior cortical vitreous removal and prolonged gas tamponade, with failure to close the hole.

INTERVENTIONS:

Treatment with TGF-beta 2 followed by gas tamponade.

OUTCOME MEASURE:

Closure of macular hole (defined as complete absence of the surrounding neurosensory detachment).

RESULTS:

Of the 17 holes 16 (94%) were closed. The average improvement in Snellen acuity was 1.76 lines; nine patients (53%) had at least two lines of improvement. The patients who gained two or more lines of acuity following surgery with TGF-beta 2 had lost significantly more lines of acuity with the primary procedure (p = 0.008) and had worse Snellen acuity following the primary procedure (p = 0.0004) than the patients who gained one line or less of acuity following surgery with TGF-beta 2. Among the patients with a final visual acuity of 20/80 or better the average duration of the hole from the onset of symptoms to the second procedure was 22.2 months.

CONCLUSIONS:

Treatment with TGF-beta 2 is a potentially useful adjuvant in the closure of persistent macular holes following failed primary surgery.

• Authors: D W Kozy, A L Maberley
• Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (Can J Ophthalmol) Vol. 31 Issue 4 Pg. 179-82 (Jun 1996) ISSN: 0008-4182 [Print] England
• PMID: 8804755 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Recombinant Proteins
• Transforming Growth Factor beta

Topics

• Aged
• Humans
• Postoperative Period
• Recombinant Proteins
• Reoperation
• Retinal Perforations (drug therapy, physiopathology, surgery)
• Transforming Growth Factor beta (therapeutic use)
• Treatment Outcome
• Visual Acuity